The tweet was deleted by the author.
But we saved everything 🙂.
Emergent Biosolutions announced it has received a modification exercising an option period under its existing delivery order with the U.S. Department of War, valued at up to 22.3 million dollars.
The company stated that the first delivery in this arrangement is valued at approximately 7.4 million dollars. This contract covers the supply of a medical countermeasure for the department.
View post on X Loading...
Emergent Biosolutions is scheduled to host its Q3 2026 earnings call on November 2 for investors and stakeholders. The company's recent engagements with government agencies have focused on supplying medical countermeasures. Updates on contract activity and financial results are expected during these upcoming disclosures.